E

Armored CAR-T cell therapies and commercial threats from the East

On launched products, armored CARs and the potential threat from China

August 16, 2018
E

Targeting immunosuppression and other stories – are we ready for prime time yet?

On targeting immunosuppression and some obscure oncogenic targets

August 9, 2018
E

Picking PARP inhibitors apart

Are the PARPi a class effect or are there real differences between them that may become more apparent in future combo studies?

August 1, 2018
E

An up and coming IO target to watch out for

Beyond PD-1 and CTLA4 there are other checkpoint and IO targets being investigated. We take a look at one of the promising ones...

July 19, 2018
E

Can we use exosomes for immune monitoring?

One of the ongoing challenges with cancer immunotherapy is monitoring response to treatment. Even if you…

June 21, 2018
E

Why don’t all cancer patients with a high TIL respond to immunotherapy?

We explore the importance of looking under the hood at various expression levels...

May 30, 2018
E

The PD-1 Gorilla is Back!

4 KOLs tell us what they really thought about the 3 studies in 1L NSCLC presented at AACR18

April 25, 2018
E

How Charles Swanton plans to revolutionize treatment of Lung and Renal cancers

What can we learn from the TRACERx studies in lung and renal cancers? Quite a lot, it seems...

April 26, 2018
E

Development of Next Generation CAR T cell therapies

A look at the history of CAR T cell therapy design and where things are headed in the future with one of the original cell therapy pioneers

May 14, 2018
E

An up and coming new player in CAR T cell therapy

A look at path to market strategies open to a small biotech in the CAR-T cell space

May 9, 2018
E

A different take on targeting cancer

How do we drive more T cells into the tumour? Here's one company who are looking to do just that.

May 8, 2018
E

A new inhibitory checkpoint target hits the clinic

Going beyond PD-1, PD-L1 and CTLA-4 to explore other inhibitory checkpoint targets that may be useful in the clinic

May 7, 2018
E

Stacking up evidence from IO clinical trials

A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18

May 3, 2018
E

Bench to bedside and back again

A look at how basic and translational evidence points towards TGFβ as a possible new target for IO combos in some tumour types

May 1, 2018
E

Targeting TGF-β and the tumour microenvironment

A look at one way with which we can target the tumour microenviroment to improve response of cancer immunotherapy

April 30, 2018
E

Can TMB help select patients for lung cancer therapy or not?

A look at TMB as an emerging biomarker for cancer immunotherapy - is it ready for prime time?

April 23, 2018
E

To be or not to be…

Answering questions on the 1L NSCLC data presented at #AACR18

April 17, 2018
E

AACR18 Red and Green Flags in 1L NSCLC

A look at the latest 1L NSCLC trial readouts

April 16, 2018
E

AACR18 Day 2 Highlights

A look at the Class of 2018 new products in development - a hit or miss?

April 16, 2018
E

AACR18: Day 1 Cancer & Immunology Symposium

A look at some new - and very early - directions in CAR T cell therapies, especially in solid tumours.

April 15, 2018
E

An under-appreciated oncology drug class

How can we improve on monotherapy with PARP inhibitors? How do we address primary and acquired resistance?

April 10, 2018
E

The path to success in 1L NSCLC

Will the results from Merck's KEYNOTE-042 study change practice in 1L NSCLC?

April 9, 2018
E

AACR18 Preview 6: Beyond epacadostat and a look at early IO-IO combinations

Beyond the news that Incyte and Merck's epacadostat plus pembrolizumab combo failed to hit its endpoints in advanced melanoma, what other IO-IO combos should we turn to?

April 6, 2018
E

AACR18 Preview 5: is TGFβ an emerging cancer target?

A look at an emerging IO target that might be useful in ceratin tumour types and patient subsets when given in combination

April 4, 2018
E

AACR18 Preview 4: a look at new developments in a key tumour type

What's hot at #AACR18 in terms of data to watch out for in a certain tumour type?

April 3, 2018
E

Innate Pharma – converting science into the clinic

An in-depth look at the French biotech company Innate Pharma and where they are now two years on from our last look at their IO pipeline.

March 27, 2018
E

The squamous and non-squamous lung cancer race continues!

A look at the key lung cancer data expected at AACR18 and what to expect from the latest squamous NSCLC

March 21, 2018
E

Challenges and Opportunities with NK cells for cancer therapeutics

Our latest primer explores NK cells and their role in oncology R&D - it's an up and coming area

March 5, 2018